Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00330200 · ClinicalTrials.gov registry record · Phase 2
Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT00330200: Clinical Trial Phase 2 study, sponsored by Ionis Pharmaceuticals.
NCT00330200 is a Phase 2 study that was terminated before completion, run by Ionis Pharmaceuticals. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00330200, a Phase 2 study, was terminated before completion, sponsored by Ionis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The aim of this study is to examine the effects of ISIS 113715 monotherapy on insulin sensitivity, glucose and lipid metabolism and energy expenditure in subjects with type 2 diabetes mellitus.
Interventions
- DRUG ISIS 113715
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2005-11-01 |
| Est. Completion | 2007-03-01 |
| Phase | Phase 2 |
Why NCT00330200 stopped before completion
NCT00330200 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which ISIS 113715 is the first listed.
NCT00330200 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00330200 about?
NCT00330200 is a clinical study titled "Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics". The aim of this study is to examine the effects of ISIS 113715 monotherapy on insulin sensitivity, glucose and lipid metabolism and energy expenditure in subjects with type 2 diabetes mellitus.
What is the current status of trial NCT00330200?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2005-11-01. Estimated completion is 2007-03-01.
What interventions are being tested in trial NCT00330200?
The interventions under investigation include: ISIS 113715 (DRUG).
Who is sponsoring clinical trial NCT00330200?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00330200's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI